Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	141.57	149.52	150.37	93.77	61.45	107.64
Short-Term Investments	335.8	350.17	443.29	319.97	597.4	116.37
Cash & Cash Equivalents	477.37	499.69	593.66	413.73	658.85	224.01
Cash Growth	-11.67%	-15.83%	43.49%	-37.20%	194.12%	-35.54%
Receivables	131.16	114.02	75.19	20.16	10.76	0
Inventory	50.77	50.27	23.92	7.95	7.06	0
Other Current Assets	31.23	3.82	45.19	25.44	14.24	6.31
Total Current Assets	690.53	667.8	737.96	467.28	690.9	230.32
Property, Plant & Equipment	14	14.58	16.74	22.56	26.32	20.51
Other Long-Term Assets	42.51	45.91	0.09	0.09	0.09	0.35
Total Long-Term Assets	56.51	60.5	16.82	22.64	26.41	20.86
Total Assets	747.04	728.3	754.78	489.92	717.31	251.19
Accounts Payable	11.53	11.45	10.4	8.69	5.5	7.43
Current Debt	3.64	3.61	4.57	6.73	5.54	3.19
Other Current Liabilities	119.63	108.48	68.27	37.93	25.81	25.61
Total Current Liabilities	134.8	123.55	83.24	53.36	36.85	36.22
Long-Term Debt	12.74	13.33	15.47	18.68	23.6	19.96
Total Long-Term Liabilities	12.74	13.33	15.47	18.68	23.6	19.96
Total Liabilities	147.54	136.87	98.71	72.03	60.45	56.18
Total Debt	16.38	16.94	20.04	25.41	29.14	23.14
Debt Growth	-11.44%	-15.48%	-21.12%	-12.82%	25.92%	-
Retained Earnings	-1,632.41	-1,617.16	-1,477.49	-1,221.23	-937.1	-710.1
Comprehensive Income	-0.43	0.1	-4.19	-0.36	0.48	0.13
Shareholders' Equity	599.5	591.42	656.07	417.89	656.86	195.01
Net Cash / Debt	461	482.75	573.61	388.33	629.71	200.87
Net Cash / Debt Growth	-11.68%	-15.84%	47.71%	-38.33%	213.49%	-42.20%
Net Cash Per Share	4.76	5.03	6.10	4.78	8.95	3.64
Working Capital	555.73	544.25	654.72	413.92	654.05	194.1
Book Value Per Share	6.19	6.17	6.98	5.14	9.34	3.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).